National and Kapodistrian University of Athens
Μελέτη της έκφρασης του CFTR γονιδίου σε μεταλλάξεις ματίσματος (splicing mutations)
Abstract
dc:descriptionThe effects of eight splicing mutations, one nonsense and 2 missense mutations on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene expression, were investigated by RT-PCR analysis of mRNA extracted from nasal epithelial cells harvested from patients harbouring the mutations. We studied 4 subjects with c.621+3A>G, one with c.2751+2T>A, one with c.296+1G>C, one with c.1898+1G>T, seven with 3120+1G>A, 3 with 1525-1G>A, eighteen with 2789+5G>A, 7 with c.711+3A>G, five with p.E822X, 7 with p.D565G and one with p.G576A and compared the results to CFTR mRNA from normal subjects. Our results show that mutations c.621+3A>G, c.2751+2T>A, c.296+1G>C, c.1898+1G>A, c.3120+1G>A that disrupt the 5’ splice donor sites of introns 4, 14a, 2, 12 and 16 respectively, and c.1525-1G>A, which disrupts the 3’ splice acceptor site of intron 9 and nonsense p.E822X all result in severe deficiency of normal CFTR mRNA. The patients with severe mutations have severe clinical phenotype with both the pancreatic and pulmonary function affected. While mutations c.2789+5G>A and c.711+3A>G result in moderate deficiency of normal CFTR mRNA and therefore milder phenotype in the patients. Finally the two missense mutations p.D565G and p.G576A also result in the production of aberrantly spliced mRNA in nasal epithelial cells lacking exon 12, by affecting the exonic splicing enhancer sequences of the exon. The effect of single nucleotide substitutions on ESE/ESS cannot be accurately predicted by either SR matrices or enhancer identification. The recognition and characterization of splicing abnormalities, caused by exon sequence variations on regulatory elements, may represent a frequent disease-causing mechanism that also relates to the phenotypic variability. This information is especially useful for phenotype prediction of patients harbouring the above mutations and for genetic counselling. By characterizing the major aberrantly splicing products of the above mutations we could design oligomeric junction probes for hybridization of sequences: exon–exon (normal); exon n-exon n+2 (skipping of 1 exon); and additional oligomeric probes covering cases where the aberrant transcript includes part of an exon or intron sequences. The CF-splicing CHIP will be developed on the NanoChip® 400 Molecular Biology Workstation which should offer accurate and rapid detection of any splicing abnormality on cDNA products of CF patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2007
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Tsiamouri, Alexia
- Τσιαμούρη, Αλεξία
Subjects
dc:subject × 21- Ρυθμιστής διαμεμβρανικής διακίνησης ιόντων
- Μελέτη έκφρασης στο επίπεδο μεταγραφής
- Μεταλλάξεις ματίσματος
- Μελέτη CFTRmRNA από επιθηλιακά κύτταρα του ρινικού βλεννογόνου
- Ανάλυση αλληλουχίας των εναλλακτικά ματισμένων μεταγραφών
- Συσχέτιση κλινικού φαινοτύπου με το ποσοστό φυσιολογικών μεταγραφών
- Διάχυτες βρογχιεκτασίες
- Παγκρεατική ανεπάρκεια
- Σχεδιασμός συνθετικών ολιγομερών για εντοπισμό παθολογικών προϊόντων
- Cystic fibrosis transmembrane conductance regulator
- Splicing mutation
- RT-PCR
- Aberrantly splicing products result in deficiency of normal CFTRmRNA
- Splicing abnormalities may represent a frequent disease-causing mechanism
- Sequencing of aberrantly splicing products
- Severe mutations have clinical phenotype with pancreatic and pulmonary function affected
- Design oligomeric probes to identify the aberrant transcripts
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Medical and Health Sciences
- Basic Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/23641